VIATRIS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
VIATRIS INC. (VTRS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 283.36 thousand shares for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2025-02-27
- VIATRIS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-12-31 was 0.00 shares.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-09-30 was 0.00 shares.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-06-30 was 0.00 shares.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2023-03-31 was 283.36K shares.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2023 was 283.36K shares.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2020 was 814.35K shares, a 1.81% decline from fiscal 2019.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2019 was 829.32K shares, a 8.39% decline from fiscal 2018.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2018 was 905.26K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 0.00 shares derived: sum of 2 quarters · filed 2025-02-27 | 0.00 shares derived: sum of 3 quarters · filed 2025-02-27 | 283.36K shares 10-K · filed 2025-02-27 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-08 | 283.36K shares 10-Q · filed 2023-11-08 | |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 283.36K shares 10-Q · filed 2023-08-07 | ||
| 2023-03-31 | 283.36K shares 10-Q · filed 2023-05-08 | |||
| 2020-12-31 | 814.35K shares 10-K · filed 2023-02-27 | |||
| 2019-12-31 | 829.32K shares 10-K · filed 2022-02-28 | |||
| 2018-12-31 | 905.26K shares 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |